Viewing data from:

TEMAZEPAM

ANDA

TEMAZEPAM | A201781 | PRINSTON PHARMACEUTICAL INC

4 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: RESTORIL(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 6 NDCs

Highest NADAC/Unit

$1.58

per ea

Lowest NADAC/Unit

$0.0729

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
43547061303TEMAZEPAM 22.5 MG CAPSULE	$1.58	EA	Generic	—	2026-10-21
43547061110TEMAZEPAM 7.5 MG CAPSULE	$0.8293	EA	Generic	—	2026-10-21
43547061410TEMAZEPAM 30 MG CAPSULE	$0.0879	EA	Generic	—	2026-10-21
43547061450TEMAZEPAM 30 MG CAPSULE	$0.0879	EA	Generic	—	2026-10-21
43547061210TEMAZEPAM 15 MG CAPSULE	$0.0729	EA	Generic	—	2026-10-21
43547061250TEMAZEPAM 15 MG CAPSULE	$0.0729	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain4 active DMFs4 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

CAMBREX PROFARMACO MILANO SRLTEMAZEPAM

DMF 43761981

FIS FABBRICA ITALIANA SINTETICI SPATEMAZEPAM

DMF 52231983

MATRIX PHARMACORP PRIVATE LTDTEMAZEPAM USP

DMF 231602009

R L FINE CHEM PVT LTDTEMAZEPAM

DMF 389982023

WYETH INCInactiveTEMAZEPAM

DMF 31931978

SANDOZ LTD PHARMACEUTICAL DIV CHEMICAL DEVELOPMENTInactiveTEMAZEPAM

DMF 55071984

WYETH-AYERST LABORATORIESInactiveTEMAZEPAM

DMF 61621986

CENTAUR PHARMACEUTICALS PVT LTDInactiveTEMAZEPAM USP

DMF 253642011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (4)

Sort:

#001 — 7.5MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 4, 2015

No patent or exclusivity listings for this strength.

#002 — 15MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 4, 2015

#003 — 22.5MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 4, 2015

#004 — 30MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 4, 2015